Abstract:BACKGROUND:Gliomas are the most common intracranial tumors and are classified as I-IV. Among them, glioblastoma multiforme (GBM) is the most common invasive glioma with a poor prognosis. New molecular biomarkers that can predict clinical outcomes in GBM patients must be identified, which will help comprehend their pathogenesis and supply personalized treatment. Our research revealed four powerful survival indicators in GBM by reanalyzing microarray data and genetic sequencing data in public databases. Moreover, it unraveled new potential therapeutic targets which could help improve the survival time and quality of life of GBM patients.MATERIALS AND METHODS:To identify prognostic signatures in GBMs, we analyzed the gene profiling data of GBM and standard brain samples from the Gene Expression Omnibus, including four datasets and RNA sequencing data from The Cancer Genome Atlas (TCGA) containing 152 glioblastoma tissues. We performed the differential analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, weighted gene co-expression network analysis (WGCNA) and Cox regression analysis.RESULTS:After differential analysis in GSE12657, GSE15824, GSE42656 and GSE50161, overlapping differentially expressed genes were identified. We identified 110 up-regulated DEGs and 75 down-regulated DEGs in the GBM samples. Significantly enriched subclasses of the GO classification of these genes included mitotic sister chromatid separation, mitotic nuclear division and so on. In KEGG pathway analysis, the most abundant terms were ECM-receptor interaction and protein digestion and absorption. WGCNA analysis was performed on these 185 DEGs in 152 glioblastoma samples obtained from TCGA, and gene co-expression networks were constructed. We then performed a multivariate Cox analysis and established a Cox proportional hazards regression model using the top 20 genes significantly correlated with survival time. We identified a four-protein prognostic signature that could divide patients into high-risk and low-risk groups. Increased expression of SLC12A5, CCL2, IGFBP2, and PDPN was associated with increased risk scores. Finally, the K-M curves confirmed that these genes could be used as independent predictors of survival in patients with glioblastoma.CONCLUSION:Our analytical study identified a set of potential biomarkers that could predict survival and may contribute to successful treatment of GBM patients.

Identification of Prognostic Model and Biomarkers for Cancer Stem Cell Characteristics in Glioblastoma by Network Analysis of Multi-Omics Data and Stemness Indices

Identification and Validation of SNHG Gene Signature to Predict Malignant Behaviors and Therapeutic Responses in Glioblastoma

Bioinformatics Analysis and Experimental Validation for Exploring Key Molecular Markers for Glioblastoma

Identify Signature Regulatory Network for Glioblastoma Prognosis by Integrative Mrna and Mirna Co-Expression Analysis.

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Identification and validation of potential prognostic biomarkers in glioblastoma via the mesenchymal stem cell infiltration level

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma

Identification of glioblastoma-specific prognostic biomarkers via an integrative analysis of DNA methylation and gene expression

CSNK1D is Associated with Stemness and Invasiveness in Glioblastoma

A Novel 16-Genes Signature Scoring System As Prognostic Model to Evaluate Survival Risk in Patients with Glioblastoma

The heterogeneous cellular states of glioblastoma stem cells revealed by single cell analysis

Machine learning-based identification of lower grade glioma stemness subtypes discriminates patient prognosis and drug response

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme

From single-cell to spatial transcriptomics: decoding the glioma stem cell niche and its clinical implications

Integrated Analysis to Evaluate the Prognostic Value of Signature Mrnas in Glioblastoma Multiforme

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Prognostic Prediction Using a Stemness Index-Related Signature in a Cohort of Gastric Cancer

Prognostic Value and Immune Cell Infiltration of Hypoxic Phenotype‐related Gene Signatures in Glioblastoma Microenvironment